sur Mainz BioMed N.V.
Mainz Biomed Partners with EDX Medical on Diagnostic Tech
Mainz Biomed N.V., a company specializing in molecular genetics diagnostics, has announced a partnership with EDX Medical Group, based in the UK. The collaboration aims to expand EDX Medical's product portfolio in the UK by utilizing Mainz Biomed’s molecular diagnostic technology. This partnership is focused on enhancing early cancer detection.
Guido Baechler, CEO of Mainz Biomed, emphasized the partnership's aim to improve cancer diagnostics access in the UK. Dr. Mike Hudson, CEO of EDX Medical, highlighted their commitment to integrating molecular biomarkers for better cancer testing.
This partnership underlines both companies' dedication to advancing diagnostic technology, potentially improving patient outcomes through early disease detection. Mainz Biomed continues to develop its diagnostic solutions, including their flagship product, ColoAlert®, for early detection of colorectal cancer.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.